Catalent Inc <CTLT.N>: Profits of 69 cents per share anticipated for fourth quarter

Feb 3 (Reuters) - Immunovant Inc: * IMMUNOVANT REPORTS FINANCIAL RESULTS AND RECENT BUSINESS UPDATES FOR THE QUARTER ENDED DECEMBER 31, 2022 * IMMUNOVANT INC - CASH BALANCE OF ABOUT $433 MILLION AS OF

Feb 3 (Reuters) - Twist Bioscience Corp: * TWIST BIOSCIENCE REPORTS FISCAL FIRST QUARTER 2023 FINANCIAL RESULTS * Q1 EARNINGS PER SHARE VIEW $-1.13, REVENUE VIEW $54.1 MILLION -- REFINITIV IBES DATA *

3 February 2023 12:46 p.m. ​All figures in US dollars. The loss announced by Immunovant Inc in the third quarter were lower than the Refinitiv mean estimate of losses. The company reported losses of -

* Immunovant Inc reported a quarterly adjusted loss of 49 cents​​ per share for the quarter ended in December. The mean expectation of eight analysts for the quarter was for a loss of 39 cents per

Feb 3 (Reuters) - Oragenics Inc: * ORAGENICS, INC. REGAINS COMPLIANCE WITH NYSE AMERICAN Source text for Eikon: Further company coverage:

Feb 3 (Reuters) - Vyant Bio Inc: * VYANT BIO INC - UNDER CASH PRESERVATION PLAN OF JAN 31, CO SEES TO INCUR ABOUT $1.4 MILLION FOR EMPLOYEE TERMINATION-RELATED COSTS IN Q1 AND Q2 OF 2023 * VYANT BIO

Feb 3 (Reuters) - Merck &amp; Co Inc: * MERCK’S KEYTRUDA® (PEMBROLIZUMAB) PLUS CHEMOTHERAPY MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AS FIRST-LINE THERAPY FOR ADVANCED OR RECURRENT

Feb 3 (Reuters) - Regeneron Pharmaceuticals Inc : * REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS * REGENERON PHARMACEUTICALS - SUPPLEMENTAL BLA FOR EYLEA TO

3 February 2023 12:33 p.m. All figures in US dollars. Neurocrine Biosciences Inc is expected to show an increase in its fourth quarter earnings to $1.14​ per share according to the mean Refinitiv

* Neurocrine Biosciences Inc is expected to show a rise in quarterly revenue when it reports results on February 6. * The San Diego California-based company is expected to report a 31.1% increase in